🏥 HEALTH, FITNESS & BIOHACKING ROUNDUP — June 08, 2026 1️⃣ THREE STUDIES DEBUNK POPULAR HEALTH TRENDS A physician breaking down three major studies that challenge mainstream wellness advice: isocaloric time-restricted eating showed no cardiometabolic benefit beyond eating less, NAD+ boosters like NMN work through gut microbes rather than direct mitochondrial support, and epigenetic "aging clocks" don't track actual metabolic improvements during weight loss. The key lesson is to measure the outcome you actually care about, not assume the mechanism delivers results. @taggehealth 2️⃣ RETATRUTIDE SHOWS 30% BODY WEIGHT LOSS Eli Lilly disclosed new data for its next-generation triple-agonist weight-loss drug retatrutide, demonstrating patients lost approximately 30% of their body weight over roughly two years of treatment. The data provides more details on safety and tolerability of the compound that could become the successor to current GLP-1 medications. @statnews 3️⃣ GLP-1 DRUGS MAY REDUCE DRUG ADDICTION Research suggests GLP-1 receptors sit in the brain's reward circuitry, meaning these drugs may act on craving itself. Among 81,617 veterans with pre-existing substance use disorders, three years of GLP-1 use was associated with 40% fewer overdoses and 50% fewer drug-related deaths — a signal that extends well beyond weight management. @jeffreytaekman 4️⃣ MAYIM BIALIK SHARES GLP-1 SIDE EFFECT STORY Big Bang Theory actress and neuroscientist Mayim Bialik publicly shared her "nightmare" experience with a GLP-1 medication, highlighting that these drugs aren't for everyone and can interact with other medications. Her story underscores the importance of individual response and the need for more diverse clinical data. @WGNNews 5️⃣ DOCTORS PRESCRIBING UNAPPROVED RETATRUTIDE CBS News investigators visited clinics advertising retatrutide in Los Angeles, only to find those promotions disappearing from websites during the investigation. Despite the FDA saying compounding the drug is illegal, some clinics continue to prescribe this unapproved weight-loss compound to patients. @ByDanielGilbert 6️⃣ RETATRUTIDE CUTS LIVER FAT BY UP TO 82% Phase 2 trial data shows retatrutide delivers dramatic reductions in liver fat associated with metabolic dysfunction: at 24 weeks, higher doses achieved 81-82% relative liver fat reduction, with sustained effects at 48 weeks. This positions the drug as potentially transformative for MASLD treatment alongside weight loss benefits. @biotides 7️⃣ INJECTION GLP-1S OUTPERFORM ORAL VERSIONS Comparison data shows injected GLP-1 drugs significantly outperform oral alternatives: tirzepatide injections hit up to 21% weight loss at 72 weeks, retatrutide delivered up to 24% at 48 weeks and 28% at 80 weeks, while oral options like orforglipron maxed out at just 12% at 72 weeks — injections remain king. @TestAlchemistx 💭 The health landscape in 2026 is rapidly evolving beyond simple weight-loss narratives. GLP-1 medications are revealing surprising secondary benefits — from reducing substance addiction to lowering cancer risk — while new triple-agonists like retatrutide push weight-loss percentages into territory previously thought impossible. Yet the regulatory landscape hasn't caught up, with unapproved compounds flooding clinics before safety data is complete. Meanwhile, rigorous studies continue to challenge wellness dogma, reminding us that correlation isn't causation and the body's mechanisms are far more complex than any single supplement or fasting protocol. Which of these health developments do you find most impactful — the addiction research or the new weight-loss drug data? 👇 #HealthTech #GLP1 #Retatrutide #WeightLoss #Biohacking #Longevity #HealthNews